Q1 2026 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2026-05-15 · accession 0001012975-26-000461
$677.1M
Reported value
10
Positions
2026-03-31
Period end
The Brief · ARCH Venture Management, LLC · Q1 2026
AI · grounded in 13F
ARCH Venture Management, LLC established a new position in Generate Biomedicines Inc GENB valued at $24.3M. The fund reduced its stake in 10x Genomics Inc TXG by 70.46%. Additionally, the manager trimmed its holding in Erasca Inc ERAS by 35.86%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $123.0M | 18.2% | 4,120,053 | Common | NONE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $116.7M | 17.2% | 3,728,738 | Common | NONE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $115.7M | 17.1% | 12,916,663 | Common | NONE |
| 29479A108 | ERAS | ERASCA INC | $114.7M | 16.9% | 7,091,557 | Common | NONE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $108.2M | 16.0% | 4,540,132 | Common | NONE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $65.1M | 9.62% | 3,247,162 | Common | NONE |
| 370920100 | GENB | GENERATE BIOMEDICINES INC | $24.3M | 3.59% | 1,944,426 | Common | NONE |
| 88025U109 | TXG | 10X GENOMICS INC | $4.6M | 0.68% | 217,834 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $2.6M | 0.39% | 8,055,916 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC | $2.1M | 0.30% | 320,482 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.